Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy

Overview of attention for article published in Ophthalmology, March 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news: 17 news outlets
twitter: 8 X users

patent: 1 patent

Readers on

mendeley: 72 Mendeley

So far, Altmetric has seen 8 X posts from 8 X users, with an upper bound of 32,427 followers.

RT @davidalmeidaMD: Pegcetacoplan slows geographic atrophy and associated with increased exudative AMD. Analysis of 246 patients from FILLY…

Pegcetacoplan slows geographic atrophy and associated with increased exudative AMD. Analysis of 246 patients from FILLY revealed intravitreal pegcetacoplan slowed GA in dose-dependent manner; associated with dose-dependent increased of exudative AMD. ht…

RT @AAOjournal: Post-hoc study of 246 pts: intravitreal pegcetacoplan slowed geographic atrophy but ↑ new-onset exudative age-related macul…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 4 additional X posts.